
Ultragenyx Pharmaceutical Inc.: updates and filings
Price
$16.48
November 20, 2026Market cap $1.7B
What Ploutos Investor adds for Ultragenyx Pharmaceutical
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Aug 4, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 3, 2026Acquisition or disposal of assets, results of operations, restructuring costsForm8-K
- Oct 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 20, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 19, 2026Other material eventsForm8-K
- Oct 14, 2026Material agreement enteredForm8-K
- Oct 7, 2026Material agreement enteredForm8-K
- Sep 17, 2026Other material eventsForm8-K
- Sep 2, 2026Other material eventsForm8-K
- Aug 19, 2026Other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 11, 2026Other material eventsForm8-K
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Results of operationsForm8-K
- Jul 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 31, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 12, 2026Shares registered for employeesFormS-8
- May 18, 2026Officer or director change, shareholder voteForm8-K
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 3, 2026 | 8-K | Acquisition or disposal of assets, results of operations, restructuring costs | Document |
| Oct 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 20, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 19, 2026 | 8-K | Other material events | Document |
| Oct 14, 2026 | 8-K | Material agreement entered | Document |
| Oct 7, 2026 | 8-K | Material agreement entered | Document |
| Sep 17, 2026 | 8-K | Other material events | Document |
| Sep 2, 2026 | 8-K | Other material events | Document |
| Aug 19, 2026 | 8-K | Other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 11, 2026 | 8-K | Other material events | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations | Document |
| Jul 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 31, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 12, 2026 | S-8 | Shares registered for employees | Document |
| May 18, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 16, 2011.
The full analysis
What do Ultragenyx Pharmaceutical's filings show?
The filings are where every one of Ultragenyx Pharmaceutical's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.